Association of the Informant-Reported Memory Decline With Cognitive and Brain Deterioration Through the Alzheimer Clinical Continuum.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
13 06 2023
13 06 2023
Historique:
received:
09
08
2022
accepted:
09
03
2023
medline:
14
6
2023
pubmed:
22
4
2023
entrez:
21
04
2023
Statut:
ppublish
Résumé
Studies are sparse regarding the association between the informant-reported subjective memory decline (informant report) and Alzheimer disease (AD) biomarkers. This study thus aimed at determining the clinical relevance of the informant report throughout the AD clinical continuum, by assessing its specific relationships with amyloid deposition, cognition, and neurodegeneration. Participants from the Imagerie Multimodale de la maladie d'Alzheimer à un stade Précoce (IMAP+) primary cohort and the Alzheimer Disease Neuroimaging Initiative (ADNI) replication cohort were included; all underwent multimodal neuroimaging and neuropsychological assessments. Follow-up data of IMAP+ participants over up to 36 months were also used for longitudinal analyses. The informant report was measured with the Cognitive Difficulties Scale (IMAP+) and Everyday Cognition (ADNI). General linear models were used to assess the cross-sectional associations between the informant report and amyloid-PET, cognitive performances, and neurodegeneration (atrophy and hypometabolism) in Alzheimer signature areas; while longitudinal links were assessed in IMAP+ with linear mixed-effects models. A total of 110 IMAP+ participants were included, including 32 cognitively unimpaired older individuals (controls, age: 70.91 ± 6.57 years, female: 50%), 25 patients with subjective cognitive decline (SCD, 65.88 ± 6.64, 40%), 35 with mild cognitive impairment (MCI, 72.49 ± 7.5, 34%), and 18 with Alzheimer-type dementia (AD dementia, 68.17 ± 8.59, 28%). Seven hundred thirty-one ADNI participants were included, including 157 controls (74.21 ± 5.95, 55%), 84 with SCD (72.00 ± 5.41, 63%), 369 with MCI (71.84 ± 7.4, 44%), and 121 with AD dementia (74.29 ± 7.75, 40%). In IMAP+, a higher informant report strongly correlated to greater amyloid-PET, specifically in patients with MCI (β = 0.48, Altogether, our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD. ClinicalTrials.gov Identifier: NCT01638949.
Sections du résumé
BACKGROUND AND OBJECTIVES
Studies are sparse regarding the association between the informant-reported subjective memory decline (informant report) and Alzheimer disease (AD) biomarkers. This study thus aimed at determining the clinical relevance of the informant report throughout the AD clinical continuum, by assessing its specific relationships with amyloid deposition, cognition, and neurodegeneration.
METHODS
Participants from the Imagerie Multimodale de la maladie d'Alzheimer à un stade Précoce (IMAP+) primary cohort and the Alzheimer Disease Neuroimaging Initiative (ADNI) replication cohort were included; all underwent multimodal neuroimaging and neuropsychological assessments. Follow-up data of IMAP+ participants over up to 36 months were also used for longitudinal analyses. The informant report was measured with the Cognitive Difficulties Scale (IMAP+) and Everyday Cognition (ADNI). General linear models were used to assess the cross-sectional associations between the informant report and amyloid-PET, cognitive performances, and neurodegeneration (atrophy and hypometabolism) in Alzheimer signature areas; while longitudinal links were assessed in IMAP+ with linear mixed-effects models.
RESULTS
A total of 110 IMAP+ participants were included, including 32 cognitively unimpaired older individuals (controls, age: 70.91 ± 6.57 years, female: 50%), 25 patients with subjective cognitive decline (SCD, 65.88 ± 6.64, 40%), 35 with mild cognitive impairment (MCI, 72.49 ± 7.5, 34%), and 18 with Alzheimer-type dementia (AD dementia, 68.17 ± 8.59, 28%). Seven hundred thirty-one ADNI participants were included, including 157 controls (74.21 ± 5.95, 55%), 84 with SCD (72.00 ± 5.41, 63%), 369 with MCI (71.84 ± 7.4, 44%), and 121 with AD dementia (74.29 ± 7.75, 40%). In IMAP+, a higher informant report strongly correlated to greater amyloid-PET, specifically in patients with MCI (β = 0.48,
DISCUSSION
Altogether, our findings suggest that the informant report is particularly relevant in patients with MCI where it strongly relates to higher amyloid-PET, indicative of impairment due to AD.
TRIAL REGISTRATION INFORMATION
ClinicalTrials.gov Identifier: NCT01638949.
Identifiants
pubmed: 37085328
pii: WNL.0000000000207338
doi: 10.1212/WNL.0000000000207338
pmc: PMC10264050
doi:
Substances chimiques
Amyloid
0
Amyloid beta-Peptides
0
Biomarkers
0
Banques de données
ClinicalTrials.gov
['NCT01638949']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2454-e2465Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Références
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Neuroimage Clin. 2016 Dec 18;13:415-427
pubmed: 28116234
Am J Alzheimers Dis Other Demen. 2014 Dec;29(8):755-61
pubmed: 24928819
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S87-98
pubmed: 26445275
Alzheimers Dement (N Y). 2018 Oct 15;4:565-574
pubmed: 30386821
J Alzheimers Dis. 2014;42(1):291-300
pubmed: 24898635
J Neurosci. 2015 Jul 22;35(29):10402-11
pubmed: 26203136
Alzheimers Dement. 2017 Mar;13(3):296-311
pubmed: 27825022
Dement Geriatr Cogn Disord. 2010;30(5):411-6
pubmed: 21071942
Stroke. 1983 May-Jun;14(3):399-401
pubmed: 6658909
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S141-50
pubmed: 26402076
Neurobiol Aging. 2003 Jan-Feb;24(1):95-103
pubmed: 12493555
Neurology. 1997 Sep;49(3):786-94
pubmed: 9305341
Brain Commun. 2021 Sep 01;3(3):fcab199
pubmed: 34704027
Alzheimers Dement. 2017 May;13(5):550-560
pubmed: 27693187
Alzheimers Dement (Amst). 2018 Mar 24;10:322-331
pubmed: 29780876
J Alzheimers Dis. 2015;43(1):121-32
pubmed: 25061054
Alzheimers Dement. 2014 May;10(3):319-27
pubmed: 23871264
Alzheimers Dement (Amst). 2016 Dec 18;5:23-34
pubmed: 28054025
J Alzheimers Dis. 2014;41(2):453-66
pubmed: 24625794
Acta Psychiatr Scand. 2014 Dec;130(6):439-51
pubmed: 25219393
Am J Geriatr Psychiatry. 2010 Aug;18(8):701-10
pubmed: 21491631
Psychol Med. 1994 May;24(2):365-74
pubmed: 8084932
Neuroimage Clin. 2013 Aug 14;3:155-62
pubmed: 24179859
J Cereb Blood Flow Metab. 1992 Jul;12(4):571-83
pubmed: 1618936
Neuropsychology. 2008 Jul;22(4):531-44
pubmed: 18590364
J Neurosci. 2012 Nov 14;32(46):16265-73
pubmed: 23152610
Alzheimers Dement. 2015 Sep;11(9):1080-9
pubmed: 25449531
Alzheimers Dement. 2014 Jan;10(1):93-8
pubmed: 23562429
Ann Clin Transl Neurol. 2019 Dec;6(12):2448-2459
pubmed: 31721455
Neurology. 1984 Jul;34(7):939-44
pubmed: 6610841
PLoS One. 2020 May 12;15(5):e0232961
pubmed: 32396544
Int J Geriatr Psychiatry. 2020 Jan;35(1):91-98
pubmed: 31650618
J Alzheimers Dis. 2018;65(3):1011-1027
pubmed: 30124444
Arch Neurol. 2001 Dec;58(12):1985-92
pubmed: 11735772
Neurol Sci. 2019 Oct;40(10):2147-2153
pubmed: 31190254
Neurology. 2020 Sep 1;95(9):e1134-e1143
pubmed: 32636322
Alzheimers Res Ther. 2019 Jul 8;11(1):61
pubmed: 31286994
Age Ageing. 2015 Nov;44(6):1012-9
pubmed: 26452663
J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):166-71
pubmed: 16421116
Lancet Neurol. 2020 Mar;19(3):271-278
pubmed: 31958406
Hum Brain Mapp. 2006 Jul;27(7):588-97
pubmed: 16247783
J Alzheimers Dis. 2019;71(3):785-795
pubmed: 31424391
Neuropsychologia. 2008;46(6):1721-31
pubmed: 18289618
Alzheimers Dement (Amst). 2015 Jun 1;1(2):242-248
pubmed: 26191540